Publication

Targeting delivery in parkinson's disease

Newland, Ben
; 
Dunnett, Stephen B.
; 
Dowd, Eilís
Repository DOI
Publication Date
2016-08-01
Keywords
lactoferrin-modified nanoparticles, factor gene-therapy, glial-cell line, stem-cells, neurotrophic factor, dopamine neurons, rat model, hemiparkinsonian rats, substantia-nigra, drug-delivery
Type
Article
Downloads
Show all metadata
Citation
Newland, Ben; Dunnett, Stephen B. Dowd, Eilís (2016). Targeting delivery in parkinson's disease. Drug Discovery Today 21 (8), 1313-1320
Abstract
Disease-modifying therapies for Parkinson's disease (PD), with the potential to halt the neurodegenerative process and to stimulate the protection, repair, and regeneration of dopaminergic neurons, remain a vital but unmet clinical need. Targeting the delivery of current and new therapeutics directly to the diseased brain region (in particular the nigrostriatal pathway) could result in greater improvements in the motor functions that characterise PD. Here, we highlight some of the opportunities and challenges facing the development of the next generation of therapies for patients with PD.
Funder
Publisher
Elsevier BV
Publisher DOI
10.1016/j.drudis.2016.06.003
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland
cbn
Collections
Externally hosted open access publications with University of Galway authors (2)